期刊
LEUKEMIA
卷 36, 期 1, 页码 236-247出版社
SPRINGERNATURE
DOI: 10.1038/s41375-021-01327-w
关键词
-
资金
- Deutsche Forschungsgemeinschaft (DFG) (NICHEM) [817/5-2, FOR2033]
- German Cancer Aid (Deutsche Krebshilfe) [70113953]
- Gutermuth Foundation
- H.W. & J. Hector Foundation (Weinheim) [M83]
- Dr. Rolf M. Schwiete Foundation (Mannheim)
- Wilhelm Sander Foundation [2020.089.1]
- Jose Carreras Leukaemia Foundation [DJCLSH03/01]
Preclinical research utilizing a patient-derived xenograft (PDX) model for myelodysplastic syndromes (MDS) demonstrates the efficacy and safety of the thrombopoietin receptor agonist eltrombopag. The study shows that eltrombopag effectively promotes thrombopoiesis in MDS PDX without impacting patients' clonal composition, suggesting the PDX model as a valuable tool for testing new therapeutic concepts in MDS before clinical trials.
Preclinical research of myelodysplastic syndromes (MDSs) is hampered by a lack of feasible disease models. Previously, we have established a robust patient-derived xenograft (PDX) model for MDS. Here we demonstrate for the first time that this model is applicable as a preclinical platform to address pending clinical questions by interrogating the efficacy and safety of the thrombopoietin receptor agonist eltrombopag. Our preclinical study included n = 49 xenografts generated from n = 9 MDS patient samples. Substance efficacy was evidenced by FACS-based human platelet quantification and clonal bone marrow evolution was reconstructed by serial whole-exome sequencing of the PDX samples. In contrast to clinical trials in humans, this experimental setup allowed vehicle- and replicate-controlled analyses on a patient-individual level deciphering substance-specific effects from natural disease progression. We found that eltrombopag effectively stimulated thrombopoiesis in MDS PDX without adversely affecting the patients' clonal composition. In conclusion, our MDS PDX model is a useful tool for testing new therapeutic concepts in MDS preceding clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据